Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Pipeline & Medicines
Product Pipeline & Portfolio
Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.